MorphoSys Obtains Patents on Antibody Technologies

MorphoSys Obtains Additional U.S. Patents on Antibody Technologies MorphoSys AG (Frankfurt Stock Exchange: MOR; Prime Standard Segment) announced today that the U.S. Patent & Trademark Office has granted two new patents, which further strengthen the Company’s IP portfolio.

These patents provide an extended protection of the MorphoSys HuCAL® (Human Combinatorial Antibody Library) technology and enlarge the potential area of application for MorphoSys’ technologies. The first new patent (US 6,696,248) entitled “Protein/(Poly)Peptide Libraries” relates to MorphoSys’ proprietary HuCAL® technology.

The patent covers the genetic constitution of synthetic, fully modular human antibody libraries based on in silico consensus sequences.

A first HuCAL® patent, which is now complemented by the new patent, was issued by the U.S. Patent Office in 2001. Besides those issued in the United States HuCAL® patents have been granted in Australia and at the European Patent Office. Furthermore MorphoSys has already received several notifications of allowance for further patent applications in the U.S. In addition, the U.S. Patent & Trademark Office granted a patent (US 6,692,935 B1) entitled “Targeted Hetero-Association of Recombinant Proteins to Multi-Functional Complexes”.

The patent covers certain methods for the development of multi-functional protein complexes, such as the combination of antibody fragments with different specificities. “Over the last few years we have built a strong intellectual property portfolio around our proprietary technology HuCAL®, which is the basis of our commercial offering”, commented Dr. Simon Moroney, Chief Executive Officer at MorphoSys AG.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
UVA research quantifies the antibody response generated by Pfizer and Moderna COVID vaccines